The scientist and clinician helped develop a new form of cancer therapy, using a monoclonal antibody to treat head, neck, colorectal, and lung cancers.

Loxo focuses on cancer treatments based on tumor genetics, which will contribute to Lilly’s push in the cancer drug space.

The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.

A case study of two patients with advanced cancer shows it might be possible to avoid a common and severe side effect of immunotherapy treatment.

Researchers use several different strategies to deliver a one-two punch.

Pharmaceutical giant Sanofi to take over hemophilia drugmaker Biovertiv, while Celgene will buy cancer drugmaker Juno Therapeutics.

The pharmaceutical firm beat out a host of potential suitors, Johnson & Johnson among them, to strike a $21 billion deal with Pharmacyclics.

The public cancer center is criticized for allegedly devoting at least $1.5 million to remodeling an executive suite.

Results of breast cancer drug trials are regularly spun to conceal bias and make the drugs seem more effective or less toxic than they really are.